BACKGROUND: Living donor liver transplantation (LDLT) in cases of hepatocellular carcinoma (HCC) that do not fulfil accepted tumor criteria continues to be a matter of controversy. The aim of this study was to evaluate survival and prognostic factors associated with a liberal exclusionary policy. MATERIAL AND METHODS: This is an analysis of data collected prospectively on 57 HCC patients who underwent LDLT at our institution between April 1998 and January 2007. RESULTS: Overall 3-year survival was 62%; this increased to 71% when 45-day mortality was excluded from the analysis. Age proved to be a predictor of survival irrespective of the 45-day mortality. In contrast, the Model for End stage Liver Disease (MELD) score predicted survival only when 45-day mortality was included in the analysis, while alpha fetoprotein (AFP) level predicted survival only when it was excluded. Significant cut-off values were patient age of over 60 years, MELD score above 22, and AFP level greater than 400 ng/ml. A scoring system was developed. Survival rate at 3 years--including 45-day mortality--was 72% for score =2 and 41% for score >2 (P = 0.0146). When 45-day mortality was excluded, the survival rate at 3 years was 90% for score =2 and 32% for score >2 (P = 0.00002). CONCLUSIONS: Our results could further enhance current guidelines on age, MELD score, and AFP level for patients with HCC being evaluated to undergo LDLT.
BACKGROUND: Living donor liver transplantation (LDLT) in cases of hepatocellular carcinoma (HCC) that do not fulfil accepted tumor criteria continues to be a matter of controversy. The aim of this study was to evaluate survival and prognostic factors associated with a liberal exclusionary policy. MATERIAL AND METHODS: This is an analysis of data collected prospectively on 57 HCC patients who underwent LDLT at our institution between April 1998 and January 2007. RESULTS: Overall 3-year survival was 62%; this increased to 71% when 45-day mortality was excluded from the analysis. Age proved to be a predictor of survival irrespective of the 45-day mortality. In contrast, the Model for End stage Liver Disease (MELD) score predicted survival only when 45-day mortality was included in the analysis, while alpha fetoprotein (AFP) level predicted survival only when it was excluded. Significant cut-off values were patient age of over 60 years, MELD score above 22, and AFP level greater than 400 ng/ml. A scoring system was developed. Survival rate at 3 years--including 45-day mortality--was 72% for score =2 and 41% for score >2 (P = 0.0146). When 45-day mortality was excluded, the survival rate at 3 years was 90% for score =2 and 32% for score >2 (P = 0.00002). CONCLUSIONS: Our results could further enhance current guidelines on age, MELD score, and AFP level for patients with HCC being evaluated to undergo LDLT.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: Glenn A Krinsky; Vivian S Lee; Neil D Theise; Jeffrey C Weinreb; Glyn R Morgan; Thomas Diflo; Devon John; Lewis W Teperman; A S Goldenberg Journal: Liver Transpl Date: 2002-12 Impact factor: 5.799
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Georgios C Sotiropoulos; Andreas Paul; Ernesto Molmenti; Hauke Lang; Andrea Frilling; Bogdan P Napieralski; Silvio Nadalin; Jürgen Treckmann; Eirini I Brokalaki; Till Gerling; Christoph E Broelsch; Massimo Malagó Journal: Transplantation Date: 2005-10-15 Impact factor: 4.939
Authors: G C Sotiropoulos; S Beckebaum; H Lang; A Frilling; E P Molmenti; V R Cicinnati; F H Saner; Y Erim; H A Baba; M Malagó; C E Broelsch Journal: Eur Surg Res Date: 2007-08-23 Impact factor: 1.745
Authors: Sung Hoon Yang; Kyung-Suk Suh; Hae Won Lee; Eung-Ho Cho; Jai Young Cho; Yong Beom Cho; In Hwan Kim; Nam-Joon Yi; Kuhn Uk Lee Journal: Surgery Date: 2007-03-23 Impact factor: 3.982
Authors: Georgios C Sotiropoulos; Eleftherios Spartalis; Nikolaos Machairas; Andreas Paul; Massimo Malagó; Markus Neuhäuser Journal: Ann Gastroenterol Date: 2018-07-27